Valence8 US’s Soleno Therapeutics SLNO Stock Holding History

Valence8 US’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-9,706	Closed	-$490K	–	56
2024 Q3	$490K	Buy	+9,706	New	+$465K	0.2%	22

Other funds holding SLNO

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Valence8 US's SLNO Position: Q4 2024 in Review

Valence8 US sold out of Soleno Therapeutics (SLNO) in Q4 2024, closing a stake of 9,706 shares — an estimated $490K sold.

Valence8 US first reported a position in SLNO in Q3 2024 and held it in 1 quarter. The position peaked at $490K in Q3 2024. 166 funds tracked by Wall St. Rank hold SLNO as of Q4 2024.

Valence8 US reported no remaining Soleno Therapeutics position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 9,706 Soleno Therapeutics shares in Q4 2024, an estimated $490K.
Valence8 US first reported a position in Soleno Therapeutics in Q3 2024 and held it in 1 quarter.
Valence8 US's Soleno Therapeutics position peaked at $490K in Q3 2024.
166 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.